SCHEMBL25933742

SCHEMBL25933742

Cc1ccc(Oc2ccc(-c3nn(C4CCN(C5CCN(C6CN(C(=O)OC(C)(C)C)C6)CC5)CC4)c4ncnc(N)c34)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 0.59
LCK P06239 3/20 0.57
SRC P12931 2/20 0.57
KDR P35968 2/20 0.57
TEK Q02763 1/20 0.57
EGFR P00533 4/20 0.56
NUDT14 O95848 2/20 0.56
NUDT5 Q9UKK9 2/20 0.56
ITK Q08881 2/20 0.54
TEC P42680 2/20 0.54
TXK P42681 2/20 0.54
BMX P51813 2/20 0.54
RIPK2 O43353 1/20 0.54
NR1I2 O75469 1/20 0.54
SLC22A3 O75751 1/20 0.54
LATS1 O95835 1/20 0.54
ABL1 P00519 1/20 0.54
ERBB2 P04626 1/20 0.54
FYN P06241 1/20 0.54
PGR P06401 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933728 0.98 BTK (0.59) BTKLCKSRCKDRTEK
SCHEMBL25933740 0.95 BTK (0.60) BTKLCKSRCKDRTEK
SCHEMBL30331632 0.94 SRC (0.60) BTKLCKSRCKDRTEK
SCHEMBL22720760 0.94 BTK (0.68) BTKLCKSRCKDRTEK
SCHEMBL29470262 0.94 BTK (0.68) BTKLCKSRCKDRTEK
SCHEMBL24196862 0.94 SRC (0.60) BTKLCKSRCKDRTEK
SCHEMBL24196848 0.93 EGFR (0.62) BTKLCKSRCKDRTEK
SCHEMBL30331321 0.93 SRC (0.60) BTKLCKSRCKDRTEK
SCHEMBL24197220 0.93 SRC (0.60) BTKLCKSRCKDRTEK
SCHEMBL22721024 0.93 BTK (0.68) BTKLCKSRCKDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885LCK 6/4885SRC 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.